Shares of RAPT Therapeutics (RAPT) surged over 100% in intraday trading when the company announced positive results for their treatment of Atopic Dermatitis.
RAPT is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases.
The company today announced that the plans to report top line data from its Phase 1b clinical trial of RPT193 in patients with moderate to severe atopic dermatitis had positive results and has hosted a conference call that showcases all the relevant information about this data study.
In the Phase 1b study, 21 patients with moderate-to-severe atopic dermatitis were treated with 400 mg of RPT193, administered orally once a day for four weeks, while 10 patients received placebo. The RPT193 group showed clear improvement in key efficacy measures compared to placebo at the end of the four-week treatment period, including improvement in the Eczema Area and Severity Index (EASI) score, validated Investigator Global Assessment (vIGA) and pruritis Numerical Rating Scale (NRS)
Based on the efficacy and safety data observed in the Phase 1b study, RAPT plans to initiate a dose-ranging Phase 2b study in patients with moderate-to-severe AD and is also planning a Phase 2a study in asthma.